MD Anderson has tapped an innovative new company to improve the efficacy of cancer treatments. Photo via mdanderson.org

The sad reality is that not every cancer responds to medication, but a new collaboration is taking steps to close the gaps for scores of patients who were previously left without a clear solution.

The University of Texas MD Anderson Cancer Center and Nexo Therapeutics announced last week that they are collaborating, a move that could lead to the discovery of therapies that could work for patients with limited treatment options.

The Colorado- and Massachusetts-based company joins forces with Houston’s cancer-fighting powerhouse after emerging from stealth with a $60 million series A.

“For many cancer patients, there are no therapies that target the fundamental drivers of their disease,” says Nexo’s founder and CEO, Andrew Phillips, in a press release. He goes on to say that the company’s innovations in covalent chemistry and chemical biology, along with cancer biology and medical chemistry allows it to advance novel therapies.

But in order to get the drugs that Nexo creates onto the market, it is taking advantage of MD Anderson’s first-rate translational research and expertise in drug development. Specifically, Nexo will work with MD Anderson’s TRACTION (Translational Research to AdvanCe Therapeutics and Innovation in ONcology) platform. The pairing will allow the two bodies to accelerate the development of small-molecule therapies through drug-enabling studies.

“Together with Nexo’s innovative platform, our integrated approach to translational research and drug development is poised to design and rapidly advance novel therapies against high priority oncology targets,” says Tim Heffernan vice president of Oncology Research for TRACTION at MD Anderson, in a press release. “This collaboration highlights our commitment to advancing innovative new medicines that address critical unmet needs for our patients.”

TRACTION is part of MD Anderson’s Therapeutics Discovery Division. It combines a team of doctors, researchers, and drug development specialists to bring therapies from discovery to clinical trials. TRACTION researchers will work with Nexo to identify cancers that might be susceptible to their treatments, then find strategies to target them, and finally use biomarkers to help optimize patient selection.

Nexo will help to provide funding to support this research and will retain rights to programs under the collaboration, and will take sole responsibility for development, manufacturing, and commercialization. Meanwhile, MD Anderson may receive royalties and future payments based on milestones as they are obtained. But the real reward will be treating patients who were previously low on options.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston healthtech startup raises $30M to scale surgical healing gel

fresh funding

Houston-based healthtech startup TYBR Health has raised a $30 million Series A round to scale its B3 GEL System, which helps protect tendons from scarring after surgery.

The round was led by Minneapolis-based Vensana Capital and Cleveland-based Mutual Capital Partners, with participation from Denver-based Neovate Capital Partners and existing investors, according to a news release from the company.

TYBR Health said it plans to use the funding to broaden the B3 GEL System's clinical applications, expand commercialization and conduct studies to evaluate its ability to protect tissue and improve healing outcomes.

"Surgeons are exceptionally good at the structural repair, but the biology that follows is what determines how it heals. That part of the equation has gone largely unaddressed ... There's a shift underway across surgical specialties, from focusing almost entirely on the mechanical repair to also weighing the biological conditions that repair needs to succeed," Tim Keane, co-founder and CEO of TYBR Health, said in the news release. "This financing lets us reach more surgeons and generate the clinical evidence to move that shift forward."

As part of the financing round, Greg Banker of Vensana Capital and Liz Todia Zambory of Mutual Capital Partners will join the TYBR board, alongside independent director Aaron Smith.

"TYBR Health is addressing a gap surgeons have lived with for a long time, with a product that fits the way they already work," Zambory, principal at Mutual Capital Partners, added in the release. "We're excited to co-lead this round and support the company's growth."

TYBR was founded in 2020 and originated from the TMCi’s Biodesign fellowship and participated in the TMC's Accelerator for HealthTech. Its B3 GEL System is a flowable extracellular matrix hydrogel designed to protect tendons, ligaments, muscles, and the surrounding soft tissue while they heal from orthopedic surgery. It received FDA 510(k) clearance last June and launched an Australian clinical trial in the fall.

The B3 GEL System has been used in hand, wrist, shoulder, foot and ankle, and sports medicine procedures since it launched, according to the company, and was first used in the clinical setting earlier this year by Dr. Tammam Hanna with Texas Tech University Health Sciences Center.

Houston space companies win NASA funding to build Mars exploration robots

mission to mars

Two Houston-area spacetech companies have landed a portion of a $17 million award from NASA to develop robots for exploring the surface of Mars, the agency announced this month.

Houston-based Inuitive Machines and Webster, Texas-based MEI Technologies, which does business as Aegis Aerospace, were among the seven companies selected to receive the funding from NASA's Science Transport and Robotic Innovation for Deployment and Exploration (STRIDE) initiative.

According to the release from NASA, the companies are tasked with creating "innovative mobility systems" that would allow future Mars missions to access more challenging terrain and difficult-to-reach regions of the planet, and to travel farther distances. NASA estimated that the work will begin this fall.

NASA solicited proposals for participants in the STRIDE initiative in January. The seven named companies are the first selected to participate in the program.

The additional five companies to receive STRIDE funding include:

"STRIDE demonstrates NASA’s commitment to strong public-private partnerships, allowing the agency to explore new approaches for Mars surface exploration while identifying key capability gaps and development needs for commercial systems that could operate and traverse realistic Martian environments," NASA shared in the announcement.

Last month, Intuitive Machines was awarded $148.3 million to deliver its Nova-C lander to the moon. The funding was part of $600 million the space agency awarded to three companies as part of its Moon Base Program and was Intuitive Machines' sixth task order under NASA's Commercial Lunar Payload Services (CLPS) program. Astrobotic was also one of the companies to land funding for the Moon Base program, as well as Austin-based Firefly Aerospace.

Around the same time, Firefly Aerospace was awarded a $13 million subcontract from NASA’s Jet Propulsion Laboratory to develop technology for NASA’s SkyFall mission to Mars. The mission aims to deploy three Mars helicopters to "perform science and demonstrate airborne subsurface mapping and resource prospecting on the planet." Read more here.